Human CD20 Antibody - Ofatumumab Biosimilar

Anti-CD20 Antibody - Ofatumumab biosimilar - CAS #679818-59-8

Anti-hCD20-Of-hIgG1 is a research biosimilar antibody to the clinical antibody Ofatumumab. Ofatumumab is a fully human type I (first generation) monoclonal antibody that mediates B cell destruction through complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC). Ofatumumab targets the human CD20 antigen found on the surface of normal and malignant B lymphocytes.  Ofatumumab has been approved by the FDA to treat chronic lymphocytic leukemia (CLL) [1-3].

Anti-hCD20-Of-hIgG1 features the variable region of Ofatumumab and a human IgG1 constant region for high effector functions. More isotypes of this antibody are available and can be used to compare several biological activities such as ADCC (see below or in the 'upon request' section).

Key features

• Each lot is functionally tested and validated
• The complete sequence of the antibody construct has been verified
• Absence of endotoxins determined by the EndotoxDetect™ assay

This antibody is suitable for effector function analysis, screening assays, and cytotoxic bio-assays. It can be used in ADCC effector activity assays in combination with Jurkat-Lucia™ NFAT-CD16 effector cells and Raji target cells.

InvivoGen also provides type I anti-hCD20 mAbs featuring the variable regions of Rituximab or Ofatumumab, with either native or engineered Fc region.

References:

1. Baig NA. et al., 2014. Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia. J Immunol. 192(4):1620-9.
2. Lin TS., 2010. Ofatumumab: a novel monoclonal anti-CD20 antibody. Pharmgenomics Pers Med. 3:51-9.
3. Winiarska M. et al., 2011. Molecular mechanisms of the antitumor effects of anti-CD20 antibodies. Front Biosci (Landmark Ed). 16:277-306.